Name | [2,5-dioxopyrrolidin-1-yl 4-(bis(4-chlorophenyl)methyl)piperazine-1-carboxylate] |
---|---|
Synonyms |
MJN110
2,5-dioxopyrrolidin-1-yl 4-[bis(4-chlorophenyl)methyl]piperazine-1-carboxylate |
Description | MJN110 is a potent and selective monoacylglycerol lipase (MAGL) inhibitor[1]. MJN110 reduces hepatic macrophage number, inflammatory gene expression and slowes down fibrosis progression[2]. |
---|---|
Related Catalog | |
In Vivo | MJN110 (i.p.; 0.0818 mg/kg; twice daily for 5.5 days) reverses chronic constriction injury (CCI)-induced mechanical allodynia and thermal hyperalgesia in a dose-dependent manner. The respective ED50 value (95% confidence limits) is 0.430 (0.233-0.793) mg/kg[1]. Animal Model: Male C57BL/6J mice ranged from 18 to 35 g[1] Dosage: 0.0818 mg/kg Administration: I.p.; twice daily for 5.5 days Result: Reversed CCI-induced mechanical allodynia and thermal hyperalgesia in a dose-dependent manner. |
References |
Density | 1.47±0.1 g/cm3 |
---|---|
Boiling Point | 561.5±60.0 °C |
Molecular Formula | C22H21Cl2N3O4 |
Molecular Weight | 462.32600 |
Exact Mass | 461.09100 |
PSA | 70.16000 |
LogP | 3.71470 |